Michael S. Kaminer - Dec 16, 2021 Form 4 Insider Report for Soliton, Inc. (SOLY)

Role
Director
Signature
/s/ Lori Bisson by Power of Attorney
Stock symbol
SOLY
Transactions as of
Dec 16, 2021
Transactions value $
$0
Form type
4
Date filed
12/17/2021, 04:09 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SOLY Stock option (right to buy) Disposed to Issuer -15K -100% 0 Dec 16, 2021 Common Stock 15K $0.13 Direct F1
transaction SOLY Stock option (right to buy) Disposed to Issuer -30K -100% 0 Dec 16, 2021 Common Stock 30K $8.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.